natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
the first fragment is a toxin A repeating domain fragment and comprises at least 100 amino acids; 
prvi fragment je fragment ponavljajuće domene toksina A;
In one embodiment, the apparatus further comprises a recirculation circuit which is adapted to return slurry from the fluid passage outlet to the mixing container. 
Uređaj prema bilo kojem od zahtjeva 11 do 17 koji dalje obuhvaća recirkulacijski krug koji je prilagođen da vraća kašu iz izlaza (5) prolaza u spremnik za miješanje.
The invention relates to compounds of Formula IA and pharmaceutically acceptable salts thereof for use in the treatment of papilloma virus infections (HPV) wherein Y1A and Y1B are -NH(Rx) and Rx is as defined in the description. 
Spoj Formule IA ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju infekcija izazvanih papiloma virusom (HPV), naznačen time, ®toY1A i Y1B su -NH(Rx);RX je nezavisno R2;R2 je (a) etil supstituiran sa C(=O)OR4, gdje je R4 metil, etil, n-propil, i-propil, i-butil, s-butil, t-butil, 1-pentil,
does not express the cell markers CD117, CD133, HLA-DR, TRA1-81, CD45, CD34 and CD31, preferably it also does not express at least one cell marker selected from the group consisting of desmin, actin HHF35, B-catenin, p63 and E-cadherin. 
ne izražava stanične biljege CD117, CD133, HLA-DR, TRA1-81, CD45, CD34 i CD31, poželjno također ne izražava barem jedan stanični biljeg odabran iz grupe koja se sastoji od dezmina, aktina HHF35, B-katenina, p63 i E-kadherina.
In one general embodiment, the present invention is directed to the sodium salt of Compound (1). 
Natrijeva sol, naznačena time, da je od spoja sljedeće formule (1): AA, s 2.
R3003 (SEQ ID NO: 4) was the most potent polypeptide tested, with a K, value of 9.54 nM. 
Polipeptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni polipeptid SEQ ID NO: 177.
three heavy chain polypeptide CDRs depicted in SEQ ID NOs: 4, 9, and 14, respectively, and three light chain polypeptide CDRs depicted in SEQ ID NOs: 27, 32, and 37, respectively; 
tri CDRa teških lanaca polipeptida prikazanih u SEQ ID NOs: 4, 9 i 14, respektivno, te tri CDRa lakih lanaca polipeptida prikazanih u SEQ ID NOs: 27, 32 i 37, respektivno;
Compound according to claim 16 wherein the bipolar disorder is selected from the group consisting of bipolar I disorder and bipolar II disorder. 
Spoj u skladu s patentnim zahtjevom 16, naznačen time što bipolami poremećaj se bira iz skupine koju čine bipolarni I poremećaj i bipolarni II poremećaj,
treating the trans-amino acid derivative of formula I or formula II, or a salt thereof with a reducing agent to give asenapine of formula A; and 
ili njegove soli, naznačen time što se navedeni postupak sastoji u: (a) obradi trans-aminokiselinskog derivata formule I ili formule I
The aqueous solution is neutralised to pH ~6 by dropwise addition of dilute hydrochloric acid and extracted with tetrahydrofuran (3x10 mL). 
Vodenu otopinu neutralizira se do pH -6 ukapavanjem razrijeđene klorovodične kiseline, te ekstrahira tetrahidrofuranom (3 x 10 ml).
In a further example, the kit may comprise a metered dose inhaler containing an aerosol comprising (A) in a propellant and a metered dose inhaler containing an aerosol comprising (B) in a propellant. 
U daljnjem primjeru, komplet može sadržavati izmjerenu dozu sredstva za inhaliranje koje sadrži aerosol sa sadržajem (A) u propelantu i izmjerenu dozu sredstva za inhaliranje koje sadrži aerosol sa sadržajem (B) u propelantu.
Following overnight incubation at 4° C., 30 uL of Protein A/G agarose beads (Pierce, Rockford, Ill.) were added to the mixture and incubated for 1 hour at 4° C. The beads were then collected by centrifugation, washed three times in lysis buffer, and resuspended in 10 uL non-reducing lithium dodecyl sulfate sample buffer (Invitrogen, Carlsbad, Calif., U.S.A.). 
Prateći inkubaciju preko noći kod 4? C, 30 uL Protein A/ G zmca agaroze (Pierce, Rockford, IL) je dodan u smjesu i inkubiran 1 sat kod 4" C. Zrnca su nakon toga prikupljena centrifugiranjem, isprana tri puta u puferu lizina, resuspendirana u 10 UL nereducirajućeg litijevog sulfata (Invitrogen, Carlsbad, California, USA).
In one embodiment the active agent is present in the formulation in stable amorphous form. 
Formulacija prema zahtjevu 1, naznačena time da je aktivna tvar u stabilnom amorfnom obliku.
A fourth embodiment provides a process for the preparation of a compound of formula (V): or a salt thereof, comprising: 
HR P20182026 T1 PATENTNI ZAHTJEVI 1. = Postupak za pripremu spoja predstavljenog formulom (V):
A vaginal suppository according to claim 1, wherein said suppository comprises lactic acid or a salt thereof in a concentration of 8 -13% by weight. 
Vaginaleta sukladno patentnom zahtjevu 1, pri tome spomenuta vaginaleta sadrži mliječnu kiselinu ili njenu sol u koncentraciji od 13-15 % po masi
The method of claim 9, further comprising packaging the thawed sample in an insulated packaging assembly. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što dodatno uključuje pakiranje odmrznutog uzorka slogu izoliranog pakiranja.
in combination with an additional therapeutic agent, wherein said additional therapeutic agent inhibits a base excision repair protein; and wherein the base excision repair protein is PARP1 or PARP2; 
u pa. ili njegova farmaceutski prihvatljiva sol; u kombinaciji s dodatnim terapeutskim sredstvom, naznačen time što navedeno dodatno terapeutsko sredstvo 15
An area bonded spunbond nonwoven fabric comprising continuous filaments of polyethylene terephthalate homopolymer including matrix filaments melt extruded from a relatively higher intrinsic viscosity polyethylene terephthalate homopolymer and binder filaments melt extruded from a relatively lower intrinsic viscosity polyethylene terephthalate homopolymer, and a multiplicity of thermal fusion bonds located throughout the fabric, the fusion bonds consisting of areas in which the binder filaments have softened and thermally fused to adjacent filaments at points of contact, and wherein the binder and matrix filaments have retained their filamentary form throughout the fabric, and wherein both the matrix and binder filaments are in a semi-crystalline state and exhibit a single melting peak as evidenced by a DSC trace. The nonwoven fabric of claim 12, wherein the matrix filaments and the binder filaments exhibit different dye uptakes. 
Plošno spojeno vretenom upredeno netkano predivo, naznačeno time, da obuhvaća neprekidne niti od polietilen-tereftalat-homopolimera uključujući matrične niti ekstrudirane taljenjem od polietilen-tereftalat- homopolimera relativno većeg unutarnjeg viskoziteta te vezne niti ekstrudirane taljenjem od polietilen-tereftalat-homopolimera relativno manjeg unutarnjeg viskoziteta, kao i mnoštvo termički staljenih spojeva koji se nalaze posvuda u predivu, gdje se staljeni spojevi sastoje od područja u kojima su se vezne niti omekšale i termički stalile sa susjednim nitima na kontaktnim točkama, te time, da su vezne i matrične niti zadržale svoj oblik niti neograničene duljine kroz cijelo predivo, te se pritom HR P20171951 T1 obje vrste niti, 1 matrične i vezne, nalaze u stanju polukristala, te one izražavaju jedinstvenu vršnu vrijednost taljenja, kako se prikazuje pomoću DSC-traga.
More particularly, the present invention relates to such a smoking article which produces an aerosol that resembles tobacco smoke, and which contains no more than a minimal amount of incomplete combustion or pyrolysis products. 
CIGARETNI SUBSTITUT (57) Sažetak: = Pronalazak se odnosi na proizvod za pušenje koji proizvodi aerosol koji je sličan duhanskom dimu, ali sadrži samo minimalnu količinu proizvoda nekompletnog sagorijevanja ili pirolize.
a central hydraulic oil feed pump which via the supply line is connected with hydraulic cylinders each having a hydraulic piston and which may be subjected to pressure by hydraulic oil; 
- > središnja punipa dovođa hidrauličkog ulja (ZGI) koja je preko dovodne linije (265) povezana s hidrauličkim cilindrima koji imaju tidrauličko klip (6, 102) 1 koj: mogu biti podvrgnut pritisku b idraničkog udja;
The process according to claim 5, characterised in that the total amount of the at least one dispersing agent added before grinding step c), or before and during step c), or before and during and/or after grinding step c), is from about 0.01 to 1.25 wt%, preferably 0.05 to 1 wt%, more preferably 0.1 to 0.7 wt%, most preferably 0.3 to 0.5 wt% based on the dry weight of the mineral material. 
Postupak prema zahtjevu 4, naznačen time da ukupna količina najmanje jednog disperzijskog sredstva koja je dodana prije koraka mljevenja c), ili prije 1 tijekom koraka c), ili prije i tijekom i/ili nakon koraka mljevenja c), je od oko 0.01 do 1.25 % tež., poželjno 0.05 do 1 % tež., poželjnije 0.1 do 0.7 % tež., najpoželjnije 0.3 do 0.5 % tež. bazirano na težini suhog mineralnog materijala,
The composition according to any of the previous claims irradiated in the range 5-25 KGy. 
Sastav ijednog od bilo kojeg prethodnog patentnog zahtjeva koji je sterilni sastav.
In certain preferred embodiments, chimerised forms of antibodies include antibodies comprising a combination of heavy chains and light chains selected from the following possibilities (i) to (ix): 
Monoklonsko protutijelo koje sadrži alotipsku modifikaciju u teškom lancu protutijela, pri čemu protutijelo sadrži kombinaciju teških lanaca i lakih lanaca odabranu iz slijedećih mogućnosti (i) do (ix):
mixing the binder of step b) with the aqueous mineral pigment material suspension of step a) and adjusting the solids content of the obtained suspension so that it is from 45 to 80 wt.-%, based on the total weight of the suspension; grinding the aqueous mineral material suspension of step c). 
Cc) miješanje veziva iz koraka b) s vodenom suspenzijom mineralnog pigmentnog materijala iz koraka a) te podešavanje sadržaja krutina dobivene suspenzije tako da bude od 45 do 80% tež., u odnosu na ukupnu težinu suspenzije; d) usitnjavanje vodene suspenzije mineralnog materijala iz koraka c), gdje se u koraku c) vezivo dodaje vodenoj suspenziji mineralnog pigmentnog u količini od 0.1 do 10.0% tež., u odnosu na ukupnu težinu suspenzije.
Animals were necropsied 72 h after the first application. 
(32) Datum podnošenja prve prijave: 15.06.2007.
The composition of embodiment 7 which is suitable for topical administration. 
Pripravak prema patentnom zahtjevu 7 koji je pogodan za topičku primjenu.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 0.05% to 0.10% of an opacifying agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (£/100 ml), otprilike 0,05 % do otprilike 0,10 % sredstva za zamućivanje.
By way of example, an initial starting dose of 12.5 mg may be administered 2 to 3 times a day. 
Samo kao primjer, inicijalna početna doza od 12.5 mg se može primijeniti 2 do 3 puta dnevno.
Additionally, the ratio of the re-circulating stream to the feed stream of said fluid may according to another aspect of the present invention be in the range 1-20, such as 1-10, and preferably within the range 1.5-7.5, such as in the range 2-6, and more preferably in the range 2.5-5. 
Metoda u skladu s patentnim zahtjevom 60, pri čemu je omjer recirkulacijskog protoka prema ulaznom protoku navedene tekućine u rasponu 1-20, kao što je 1-10, a poželjno unutar raspona 1.5-7.5, kao što je u rasponu 2-6, a još poželjnije u rasponu 2.5-5, prema masi/volumenu.
TO2006A000491, the wind system 1 according to the present invention is improved in the following aspects: 
Vjetreni sustav (1) prema zahtjevu 14, naznačen time da spomenuti prijenosni sustav uključuje:
No. 5,470,566, which discloses an anticariogenic chewing gum comprising a gum base, a taste enhancer and urea for neutralizing dental plaque. 
- US 5,470,566, koji opisuje antikariogenu žvakaću gumu koja sadrži gumenu bazu, pojačivač ukusa i ureu za neutralizaciju dentalnih plaka.
The immunogenic composition of claim 7 wherein the H. influenzae b capsular saccharide is conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što svaki od najmanje jednog N. meningitidis saharida je konjugiran s proteinom-nosačem, kojeg se bira iz skupine koju čine TT, DT, CRM197, fragment C od TT, protein D, OMPC i pneumolizin.
The fastening bracket according to claim 1, wherein when the side member (21) of the chair is disposed at an angle so as to be vertically diagonal, at least one of the front side piece (12) and the rear side piece (13) is adapted to be oriented vertically diagonal at substantially the same angle as the side member (21). 
Nosač za pričvršćivanje prema bilo kojem od zahtjeva 1 do 6, naznačen time da kada je bočni element (21) je okomito dijagonalan, prednji bočni dio (12) i/ili stražnji bočni dio (13), je okomito dijagonalan pod istim kutom kao navedeni bočni element (21).
Conveniently, when the reducing agent is formic acid, protecting groups such as tert-butoxycarbonyl on the NH group to be alkylated (for example present from the synthesis of the starting material) may be removed in-situ during the reaction. 
Kada se kao reducirajući agens koristi mravlja kiselina, zaštitne skupine poput fercbutoksikarbonila na NH skupini koju se alkilira (koja je, naprimjer, prisutna kao posljedica sinteze polaznog materijala), mogu se prikladno ukloniti in situ tijekom reakcije.
The transfer vehicle of claim 4, wherein the RNA is mRNA. 
Nosač transfera prema zahtjevu 4, naznačen time što RNK je iRNK.
The apparatus of claim 1 wherein the biologically active or chemical substance comprises at least in part, living organisms. 
Sustav prema zahtjevu 1, naznačen time što se biološki aktivna ili kemijska supstanca sastoji bar dijelom od živih organizama.
The method of claim 13, wherein said broomrape is selected from the group consisting of: Orobanche cumana and Orobanche cernua. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što se navedeni volovod bira iz skupine koju čine: Orobanche cumana i Orobanche cernua.
The process of claim 1, wherein the remineralized water has one or more of a Langlier Saturation Index from −0.2 to 0.2, a Slit Density Index SDI15 below 3, and a Membrane Fouling Index MFI0.45 below 2. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu remineralizirana voda ima Indeks onečišćivanja membrane MFI0.45 ispod 4, poželjno ispod 2.5, najpoželjnije ispod 2.
The apparatus according to claim 14, wherein the predetermined portion consists of a particular set of unallocated subscriber numbers or the predetermined portion is dynamically defined from among unallocated subscriber numbers. 
Uređaj prema zahtjevu 9 ili 10, gdje se unaprijed određeni dio sastoji od određenog seta nedodijeljenih telefonskih brojeva ili je unaprijed određeni dio dinamički definiran od strane procesora iz nedodijeljenih pretplatničkih telefonskih brojeva.
The sweetener composition can only partially replace the functionality of sucrose such as sweetness. 
Sastavina sladila može samo djelomice nadomjestiti HR P20080437 T3 funkcionalnost saharoze, npr. njenu slatkoću.
the hemitartrate salt of a compound represented by the following structural formula: 
Prvo terapijsko sredstvo predstavljeno sa slijedećom strukturnom formulom: O
A peptide consisting of the amino acid sequence according to SEQ ID No. 22. 
peptida koji se sastoji od sekvence u skladu s SEQ ID br. 14,
The floating lake system of claim 1, wherein the bottom comprises one or more cushion-type cells capable of providing a stable bottom. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što dno (2) sadrži jednu ili više ćelija tipa jastuka koje mogu osigurati stabilno dno (2).
In some embodiments, a subject method involves introducing into a host cell (or a population of host cells) one or more nucleic acids comprising nucleotide sequences encoding a DNA-targeting RNA and/or a variant Cas9 site-directed polypeptide. 
(a) se kod jednoga ili više polinukleotida DNK koji kodiraju navedenu RNK koja cilja na DNK, radi o jednom ili više rekombinantnih vektora ekspresije; i/ili (b) se kod jednoga ili više polinukleotida koji kodiraju navedeni kimerni polipeptid Cas9, radi o jednom ili više rekombinantnih vektora ekspresije.
The IL-23 antagonist of Claim 10, wherein the monoclonal antibody or monoclonal antibody fragment is covalently linked to an albumin molecule. 
Uporaba u skladu sa zahtjevom 62, naznačena time, da se monoklonsko antitijelo ili fragment monoklonskog antitijela veže na i inhibira djelovanje IL-17.
In Block 603, in the X2 handover completion stage, on receiving a response for handover completion (e.g. handover complete Ack) sent by the SGW, the target eNB determines that the sending of user data packets from the source eNB to the target eNB (i.e., X2-interface data packets) is completed according to the GTP_U sequence number of the next user data packet to be sent by the source eNB and the GTP_U sequence number of the first user data packet sent by the SGW, and then sends user data packets delivered by the SGW (i.e., S1-interface data packets) to the UE. 
Postupak prema zahtjevu 1, naznačen time da, prije prijema posebnog paketa podataka, postupak nadalje sadrži: prijem (303), od izvornog eNB, poseban paket podataka od SGW, pri čemu se poseban paket podataka generira pomoću SGW; regeneriranje (3031), od izvornog eNB, specijalnog paketa podataka sa završnom oznakom u skladu sa posebnim paketom podataka poslanim od SGW, pri čemu regenerirani posebni paket podataka ne sadrži korisničke podatke i nosi broj PDCP sekvence slijedećeg paketa korisničkih podataka koji se treba poslati od izvornog eNB; slanje, od izvornog eNB, regeneriranog specijalnog paketa podataka prema ciljnom eNB.
It could include a digital display 84 integrated with controller 80 or connected through a cable 86. 
On može imati digitalni displej 84 integriran s kontrolorom 80 ili povezan preko kabla 86.
SOCl2 (930 mmol) was added and the mixture was heated at 65 °C for 5h. 
SOCIL (930 mmol) se doda i smjesa se grije na 65 "C kroz 5 sati.
discharge of the emulsion of fluid components from the washing chamber (101) through the outlet (103) of the washing and separating container (1); 
pražnjenja emulzije od tekućih komponenti iz komore (101) za ispiranje kroz odvod (103) spremnika (1) za ispiranje i odvajanje;
A method of treating according to clause 29, wherein said neoplastic disease is lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal tumor, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome, or myeloproliferative disease. 
Sastav za upotrebu u postupku prema zahtjevu 20, naznačeno time da je spomenutna neoplastična bolest rak pluća, Tak glave 1 vrata, rak središnjeg živčanog sustava, rak prostate, rak testisa, rak debelog crijeva, rak gušterače, rak jetre, rak želuca, rak žučnih vodova, rak jednjaka, gastrointestinalni stromalni tumor, rak dojke, rak grlića maternice, rak jajnika, rak maternice, leukemija, limfomi, multipli mijelomi, melanom, rak bazalnih stanica, rak pločastih stanica, rak mokraćnog mjehura, rak bubrega, sarkom, mezoteliom, timom, mijelodisplastični sindrom, ili mijeloproliferativna bolest.
is selected from the group consisting of hydrogen, and C1-4 alkyl; 
R7 se bira iz skupine koju čine vodik i C1-4 alkil;
A nucleic acid molecule coding for the anti-RGMa antibody or an antigen-binding fragment thereof according to claim 1 . 
Molekula nukleinske kiseline koji kodira dio proteina od tog protu-RGMa protutijela ili njegov fragment koji veže antigen sukladno bilo kojem od patentnih zahtjeva 1 do 4.
An anticancer agent according to claim 16, wherein the cancer is any selected from lung cancer, breast cancer, prostate cancer, colon cancer, acute myeloid leukemia, malignant lymphoma, retinoblastoma, neuroblastoma, and sarcoma. 
Protukancerogeni agens u skladu s patentnim zahtjevom 13, pri čemu je karcinom bilo koji odabran između karcinoma pluća, karcinoma dojke, karcinoma prostate, karcinoma kolona, akutne mijeloične leukemije, malignog limfoma, retinoblastoma, neuroblastoma i sarkoma. HR P20140409 T1
The shelf according to claim 1, wherein at least two hooks on horizontally opposite sides of the plate are identical and, when inserted into the plate, are horizontally mirrored. 
Polica (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu su najmanje dvije kuke (20) na suprotnim stranama ploče (11) identične i, kada se ugrade u ploču (11), predstavljaju kao odraz u ogledalu.
The mechanical fitting 220 may include a transverse membrane 250 to prevent the backflow of fluid from the hysteroscope from spilling out onto the operator and the control device of the intrafallopian contraceptive delivery device. 
Stabilizacijska naprava iz patentnog zahtjeva 1, pri čemu je mehaničko pričvršćenje (220) prilagođeno za sprečavanje povrata tekućine iz stabilizacijske naprave.
Liquid receiving system according to claim 1 or 2, wherein the elements (39) have side wall openings (11-13). 
Sustav za prihvat tekućina u skladu s patentnim zahtjevom 1 ili 2, naznačen time što clementi (39) imaju otvoro na bočnim stranama (11-13).
A is —N═, is selected from the group consisting of phenyl optionally substituted with methoxy or 1 to 3 independently selected chloro or fluoro substituents; pyrazol-4-yl optionally substituted with 1 to 3 methyl or ethyl groups; imidazolyl optionally substituted with 1 or 2 methyl or ethyl groups; pyridyl optionally substituted with fluoro or chloro; and thienyl; 
R1 se bira iz skupine koju čine fenil, izborno supstituiran s metoksi ili 1 do 3 neovisno odabrana supstituenta, klora ili fluora; pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; imidazolil, izborno supstituiran s 1 ili 2 metila ili etila; piridil, izborno supstituiran s fluorom ili klorom; te tienil;
Example compounds of formula le 
Spoj formule I, zA
The pharmaceutical composition of any one of claims 10-12 for use in a method for treating and/or preventing the symptoms of phenylketonuria in a subject, optionally wherein: 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 9-11 za upotrebu u tretmanu i/ili sprječavanju simptoma fenilketonurije kod subjekta, opcionalno naznačena time da:
A therapeutically effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof for use in treating purpura in a subject, wherein purpura is selected from solar purpura, actinic purpura, senile purpura, Bateman's purpura, laser-induced purpura, purpura caused by physical trauma, purpura caused by physical trauma to the skin, cutaneous vasculature, and/or surrounding tissues, purpura caused by a medical procedure, purpura caused by a surgical procedure, and combinations thereof. 
Terapeutski učinkovita količina agonista alfa adrenergijskog receptora ili njegove farmaceutski prihvatljive soli za uporabu u liječenju purpure kod subjekta, naznačena time što je purpura odabrana od solarne purpure, aktinske purpure, senilne purpure, Batemanove purpure, laserski inducirane purpure, purpure uzrokovane fizičkom traumom, purpure uzrokovane fizičkom traumom kože, kožne vaskulature, i/ili okolnih tkiva, purpure uzrokovane medicinskim postupkom, purpure uzrokovane kirurškim zahvatom i njihovim kombinacijama.